CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) — F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that management will be presenting a corporate overview and be available for 1-on-1 meetings at the 32nd Annual Oppenheimer Healthcare Conference taking place virtually on March 15-17, 2022.
32nd Annual Oppenheimer Healthcare Conference (virtual)
Date: March 15th, 2022
Presentation Time: 2:40pm
Speaker: Eliot Forster, Chief Executive Officer
Format: Company Presentation
Webcast Registration Link.
A replay will be available following the presentation for 90 days
About F-star Therapeutics, Inc.
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer. F-star is pioneering the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in cancer therapy. The Company has four second-generation immuno-oncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star’s proprietary antibody discovery platform is protected by an extensive intellectual property estate. F-star has over 500 granted patents and pending patent applications relating to its platform technology and product pipeline. The Company has attracted multiple partnerships with biopharma targeting significant unmet needs across several disease areas, including oncology, immunology, and CNS.
For further information, please contact:
For investor inquiries:
VP Investor Relations & Communications
+1 240 543 7970
LifeSci Advisors LLC
+1 917 355 2395
For media inquiries:
Shik Communications LLC